Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06323876 · ClinicalTrials.gov registry record
The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis
A clinical trial of Idiopathic Pulmonary Fibrosis, sponsored by University of Virginia.
- Recruiting
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT06323876 is a study of Idiopathic Pulmonary Fibrosis that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 160 participants, below the 748-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06323876, a study of Idiopathic Pulmonary Fibrosis, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study involves obtaining 2 chest CT scans; a historical baseline CT within ±1 year of enrollment into PRECISIONS, and a follow-up CT (either historical or prospective) 12 months ± 180 days after the baseline CT. Many IPF patients will have a CT scan every 12 months for disease monitoring and cancer screening. Participants will have the option to share historical CTs only or they can choose to have a research CT done for the follow-up scan, if a scan for clinical purposes is not available.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood Draw
- DIAGNOSTIC_TEST HRCT
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-06-20 |
| Est. Completion | 2029-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06323876
The ClinicalTrials.gov registry entry for NCT06323876 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 748-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (79% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Blood Draw is the first listed.
NCT06323876 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06323876 about?
NCT06323876 is a clinical study titled "The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis". This observational study involves obtaining 2 chest CT scans; a historical baseline CT within ±1 year of enrollment into PRECISIONS, and a follow-up CT (either historical or prospective) 12 months ± 180 days after the baseline CT. Many IPF patients will have a CT scan every 12 months for disease mon...
What is the current status of trial NCT06323876?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2024-06-20. Estimated completion is 2029-05.
What conditions does trial NCT06323876 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT06323876?
The interventions under investigation include: Blood Draw (DIAGNOSTIC_TEST), HRCT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06323876?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06323876 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.